Biosimilars have recently seen increased momentum in the United States, offering life-changing, lower-cost treatment options. However, barriers to uptake remain, preventing many patients from benefiting fully. Join Sandoz's Dr. Sonia T. Oskoeui and the FDA's Dr. Sarah Yim as they explore the value these medicines provide to patients, their role in the health care system, and strategies to advance their adoption.
Don't miss this opportunity to gain insights from industry leaders and participate in a critical discussion about the future of biosimilars.
%20MH%20Testing/Larger%20Header%20Logos/STAT_BrandStudio2.png?height=88&upscale=true&name=STAT_BrandStudio2.png){kind=small}
.jpg?noresize&width=1200&upscale=true&name=SBS_Sandoz_TallEmail%20(2).jpg)
No comments